Clinical trial
Effectiveness of Rituximab in Pediatric OMS Patients.
NCT00244361 · National Pediatric Neuroinflammation Organization, Inc., Other · Completed
Key facts
| NCT number | NCT00244361 |
|---|---|
| Title | Effectiveness of Rituximab in Pediatric OMS Patients. |
| Official title | A Phase I Clinical Trial of Rituximab for Pediatric Opsoclonus-Myoclonus Syndrome |
| Lead sponsor | National Pediatric Neuroinflammation Organization, Inc., Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 25 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 26, 2005 |
| Last update posted | May 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: